Back to Search
DANIEL PETRYLAK, M.D.
M.D.
Medical Oncology Physician
NPI: 1659387306IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology Physician
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
164174(NY)
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
51405(CT)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
CLVLND CLINIC LERNER COLLEGE OF MED OF CASE WSTN RSV UNIVERSITY
Class of 1985
Research & Publications (20)
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.
PMID 19380444·J Clin Oncol·2009
3-trial
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.
PMID 19167733·J Urol·2009
2-rct
Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study.
PMID 19536904·Cancer·2009
3-trial
Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy.
PMID 18501081·Clin Genitourin Cancer·2008
3-trial
Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder.
PMID 18930256·J Urol·2008
3-trial
Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy.
PMID 18501080·Clin Genitourin Cancer·2008
3-trial
Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).
PMID 18006112·Lung Cancer·2008
3-trial
Treatment of metastatic urachal carcinoma in an elderly woman.
PMID 18097457·Nat Clin Pract Oncol·2008
5-case
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
PMID 18309951·J Clin Oncol·2008
6-review
Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel.
PMID 17960793·Cancer·2008
4-observational
Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer.
PMID 18710748·J Urol·2008
3-trial
Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy.
PMID 17785568·Clin Cancer Res·2007
8-other
Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed.
PMID 17822456·BJU Int·2007
4-observational
Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma.
PMID 17667529·J Immunother·2007
3-trial
Clinical trials in metastatic hormone-refractory prostate cancer: improving docetaxel therapy by targeting bone-related growth factors.
PMID 17430692·Curr Oncol Rep·2007
8-other
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study.
PMID 17437819·J Urol·2007
3-trial
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.
PMID 17538166·J Clin Oncol·2007
3-trial
Activation of targeted necrosis by a p53 peptide: a novel death pathway that circumvents apoptotic resistance.
PMID 17636258·J Biol Chem·2007
8-other
Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
PMID 17868721·J Urol·2007
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 35 PARK STREET, NP-4
NEW HAVEN, CT 06510 - Phone
- (203) 200-4822
Quick Facts
- NPI
- 1659387306
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 41
- Publications
- 20
Are you this provider?
Claim Your Profile